Jenner & Block

Jenner & Block is a prominent BigLaw firm headquartered in Chicago, Illinois, with an expansive footprint across seven offices in Century City, Chicago, London, Los Angeles, New York City, San Francisco, and Washington, D.C.. The firm is recognized for its overall strength, ranking as the 83rd largest by gross revenue on The American Lawyer's 2025 Am Law 200 list, and #4 on The American Lawyer's 2025 A-List, which evaluates firms excelling in financial success, talent, culture, and social responsibility. With over 500 attorneys globally, including more than 400 focused on litigation and disputes, Jenner & Block is a significant player in the legal landscape.

The firm’s IP litigation practice demonstrates broad capabilities across diverse technology sectors. Its experience spans life sciences, including biotechnology, pharmaceuticals, and medical devices, as evidenced by its involvement in biosimilar litigations. Jenner & Block also handles complex patent disputes in electronics, software, telecommunications, and portable devices, seen in cases involving video streaming and AI technology. Beyond patents, the firm maintains strong practices in copyright, trademark, trade secrets, and International Trade Commission (ITC) investigations.

Analysis of tracked cases indicates a notable preference for defending operating companies, with four appearances on the defendant side versus one on the plaintiff side. The firm's patent litigation team explicitly states it "asserts and defends patents against both competitors and non-practicing entities". This defensive strength is highlighted by a win for Volvo Cars, where the firm secured a motion to dismiss for improper venue in a patent infringement suit brought by Intellectual Ventures.

In significant cases, Jenner & Block represented Samsung Bioepis Co., Ltd. in its biosimilar litigation with Regeneron Pharmaceuticals, Inc. over the EYLEA® drug. This matter involved a preliminary injunction granted against Samsung Bioepis which was affirmed by the Federal Circuit in January 2025. The case ultimately resolved via a settlement in February 2026, allowing Samsung to launch its biosimilar in January 2027. The firm also defended Roku, Inc. against VideoLabs, Inc., a multi-patent streaming dispute that was dismissed with prejudice in December 2024, following 442 days of litigation and associated PTAB proceedings.

Jenner & Block has a robust PTAB and IPR practice, frequently utilizing these post-grant review mechanisms as part of its litigation strategy. The firm's website and Chambers USA explicitly highlight its experience in IPR and PTAB trials. For instance, in VideoLabs, Inc. v. Roku, Inc., the district court case was stayed pending the conclusion of several inter partes review (IPR) proceedings involving five of the seven asserted patents. Key partners in the patent litigation practice include Reginald Hill, who co-chairs the patent group and is recognized for his expertise with technology sector clients, and Benjamin J. Bradford, a partner also noted in IAM Patent 1000 for his patent work. Adam G. Unikowsky is another prominent attorney involved in significant patent cases and is known for his appellate work. Additionally, Mark G. Davis joined the firm to boost its patent litigation trial practice and launch its International Trade Commission (ITC) practice.